Webcast complete data MG Ph2 clinical trial efgartigimod @ AAN, April 24th - 1:00 PM PT, LA


Partnering is central to our corporate development strategy. Our development as a company has benefited from strategic partnerships and licensing that have expanded our scientific and technological expertise and contributed to our antibody product portfolio. argenx is always open to exploring innovative ideas – at all stages of development – that we  can help to move forward.

argenx focuses on maximizing the value of its proprietary product pipeline and technologies via two routes:

Product Partnering: argenx seeks collaborative partnerships with pharma companies that enable us to develop and commercialize differentiated therapeutic antibody candidates on either a risk-sharing or out-licensing basis.

Technology Partnering: argenx builds high-value strategic collaborations for both target assets and complementary technologies – to create the next generation of antibody therapeutics.

For more information on partnering opportunities, please contact:

Debbie Allen, PhD
VP, Business Development

Arjen Lemmen
Director Business Development